Atomo Diagnostics Limited (ASX:AT1)

Market Cap	24.33M +111.5%
Revenue (ttm)	3.92M -7.0%
Net Income	-3.98M
EPS	-0.01
Shares Out	901.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,576,783
Average Volume	3,491,243
Open	0.0270
Previous Close	0.0270
Day's Range	0.0270 - 0.0280
52-Week Range	0.0140 - 0.0480
Beta	1.22
RSI	38.54
Earnings Date	Apr 28, 2026

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In fiscal year 2025, Atomo Diagnostics's revenue was 3.79 million, a decrease of -7.20% compared to the previous year's 4.09 million. Losses were -4.97 million, -27.41% less than in 2024.